

**The Role of Personality Traits in Reporting the Development of Adverse Drug Reactions: A Prospective Cohort Study of the Estonian General Population**

Anu Realo, Henriët van Middendorp, Liisi Kõöts-Ausmees, Jüri Allik, Andrea W. M. Evers

*BMJ Open*

**Supplementary Table S1**

*Descriptive Statistics of the NEO PI-3 Scales for Self- and Informant-Ratings*

NEO PI-3 Scales	Self-Ratings			Informant-Ratings			$r_{xy}$
	$M$	$SD$	$\alpha$	$M$	$SD$	$\alpha$	
Neuroticism	84.61	24.26	.93	81.23	25.01	.93	.55
Extraversion	98.09	25.25	.92	105.65	26.00	.93	.65
Openness to Experience	100.76	20.86	.89	95.19	19.90	.89	.61
Agreeableness	122.43	16.59	.84	122.01	22.52	.92	.46
Conscientiousness	122.07	21.30	.91	130.47	24.52	.93	.50

*Note.*  $N = 1357$ . NEO PI-3 = The NEO Personality Inventory-3;  $\alpha$  = Cronbach's alpha;

$r_{xy}$  = self-informant correlation.

## Supplementary Table S2

### *The Descriptive Statistics of Health Indicators at T1 and T2*

	T1		T2		<i>F</i>	<i>df</i>	<i>p</i>	<i>r</i> <sub>T1-T2</sub>
	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>				
<b>Health Indicators</b>								
Number of EHIF diagnoses	5.45	4.52	5.50	4.65	0.23	1356	.632	.58***
Number of medicines taken	1.49	2.28	2.40	1.78	197.17	1356	< .0001	.57***
Body Mass Index	26.90	5.06	27.92	5.63	209.21	1353	< .0001	.89***
Systolic Blood Pressure	127.81	17.23	133.55	19.97	118.73	1353	< .0001	.47***
Diastolic Blood Pressure	78.69	10.74	82.87	11.23	155.64	1353	< .0001	.37***

\*\*\*  $p < .0001$

*Note.* T1 = first measurement; T2 = second measurement (on average 5.3 years after T1); Number of EHIF diagnoses = the number of diagnoses recorded in the Estonian Health Insurance Fund for the year of data collection; Number of medicines taken = the number of medicines taken during the previous two months, either regularly or for treating specific diseases; *df* = degrees of freedom;  $r_{T1-T2}$  = correlation between the two measurements.

### Supplementary Table S3

*Frequency of Self-Reported Adverse Drug Reactions at T1 and T2 Coded by the ICD-10*

	<b>T1</b>		<b>T2</b>	
	<b>(n = 240)</b>		<b>(n = 524)</b>	
L20-L30: Dermatitis and eczema	39	16.3%	120	22.9%
L50-L54: Urticaria and erythema	31	12.9%	18	3.4%
R10-R19: Symptoms and signs involving the digestive system and abdomen	29	12.1%	93	17.7%
R50-R69: General symptoms and signs such as fever, headache, pain etc.	29	12.1%	87	16.6%
R00-R09: ADRs involving the circulatory and respiratory systems	26	10.8%	39	7.4%
R20-R23: Symptoms involving the skin and subcutaneous tissue not classified elsewhere	14	5.8%	36	6.9%
R40-R46: Symptoms involving cognition, perception, emotional state, and behaviour	7	2.9%	27	5.2%
T78-T80: Unclassified ADRs	7	2.9%	4	0.8%
L10-L14: Bullous skin disorders	4	1.7%	0	0%
G20-G26: Extrapyrarnidal and movement disorders	4	1.7%	0	0%
G40-G47: Episodic and paroxysmal disorders	4	1.7%	5	1.0%
J30-J39: Other diseases of upper respiratory tract	4	1.7%	10	1.9%
K20-K31: Diseases of oesophagus, stomach and duodenum	3	1.3%	8	1.5%
K55-K64: Other diseases of intestines	3	1.3%	10	1.9%
Other ADRs	36	14.8%	67	12.8%

*Note.* ICD-10 = the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD); T1 = first measurement; T2 = second measurement (on average 5.3 years after T1). The ADRs are ordered by the frequency at T1.